These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 7656127)

  • 1. A star rises, another fades.
    Neumann ME
    Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicare and erythropoietin.
    Steinbrook R
    N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
    Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
    [No Abstract]   [Full Text] [Related]  

  • 4. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update to Epogen information in article on future drug expenditures.
    Evens PE
    Am J Health Syst Pharm; 1995 Jun; 52(12):1348-9. PubMed ID: 7656127
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The drug add-on component--have all provider types seen budget neutrality?
    Mentz K
    Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646
    [No Abstract]   [Full Text] [Related]  

  • 9. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of dialysis treatments for patients with end-stage renal disease in France.
    Jacobs C
    Nephrol Dial Transplant; 1997; 12 Suppl 1():29-32. PubMed ID: 9075226
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.